The FDA has cleared Cynosure’s (NSDQ:CYNO) 532 nm Laser Delivery System for its PicoSure tattoo-removal technology platform.

Cynosure said the regulatory win will enable the PicoSure system to remove all colors of ink in fewer sessions.

The company plans to introduce the new system at the American Academy of Dermatology’s annual meeting, to be held March 20-24 in San Francisco.

“The new 532 nm Laser Delivery System further builds on the clinical and commercial success of the 755 nm PicoSure for the removal of tattoos and benign pigmented lesions, as well as the treatment of acne scars and wrinkles,” said Cynosure CEO Michael Davin, in a release. “We are pleased to offer this system as an upgrade to our current PicoSure customer base.”

Last fall, Cynosure expanded it reach into radio frequency-based devices when it acquired Ellman International for $13.2 million.